Navigation Links
Exelixis Announces Third Quarter 2007 Financial Results and Business Update
Date:11/5/2007

tended by one year our research collaboration with Bristol-Myers

Squibb (BMS) to develop and commercialize novel therapies targeted

against the Liver X Receptor. As a result of the extension, we expect

to receive additional research funding in the amount of $7.5 million.

BMS also has the option to extend the collaboration by an additional

year.

* Our wholly-owned subsidiaries Exelixis Plant Sciences, Inc. and

Agrinomics, LLC entered into a transaction with Agrigenetics, Inc., a

wholly-owned subsidiary of The Dow Chemical Company, which included

the sale of tangible and intangible assets and a research funding

agreement focused on the development of new tools for gene discovery

and validation of novel crop traits.

* We closed a public equity offering of seven million shares of common

stock, with net proceeds of approximately $71.9 million, after

deducting offering expenses.

Recent Developments

We presented phase 2 data for XL647 and XL880, and phase 1 data for XL184, XL765 and XL147 at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco. In total, 13 abstracts were accepted for poster presentation at the conference, reporting data from clinical trials or preclinical studies of XL880, XL647, XL184, XL147, XL765, XL820, XL844 and XL518.

We also announced that a recently completed phase 2 trial of XL784 did not meet its primary endpoint of reducing proteinuria compared with placebo in patients with proteinuria associated with diabetic nephropathy. Various subgroup analyses suggest that the compound may have potential to benefit patients with this disease. We submitted the XL784 data report to GSK on October 22, 2007 and GSK has 90 days from the date of submission of the data report to determine whether it will select XL784 for further clinical development and
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
2. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
3. Exelixis Announces Closing of Public Offering of Common Stock
4. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
5. Exelixis Announces November 5 Webcast of its 2007 Third Quarter Financial Results Conference Call
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... MA -- Trillions of bacteria live in each person,s ... help digest food and stave off harmful infections, but ... , To help shed light on the role of ... associate professor Eric Alm recently tracked fluctuations in the ... year. The findings, described in the July 25 issue ...
(Date:7/25/2014)... 25, 2014 The Conferee Networking committee ... for Conferee Networking. These two-hour sessions provide a unique ... and resolve problems, discuss new techniques, or brainstorm new ... submit a topic for consideration is August 31, 2014, ... The Conferee Networking committee will review the topics, and ...
(Date:7/25/2014)... -- Sinovac Biotech Ltd. (Nasdaq: SVA ), a ... , today announced that it will release its unaudited financial ... market close on Thursday, August 14, 2014 EDT. The Company ... on Friday, August 15, 2014, at 8:00 a.m. EDT (Friday, ... review the Company,s financial results and provide an update on ...
(Date:7/24/2014)... MENLO PARK, Calif. , July 24, 2014 ... biotechnology company in the emerging field of regenerative ... live webcast of a presentation to investors on ... 1:30 p.m. PDT.  The presentation will include an ... pipeline. To access the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics ...
Breaking Biology Technology:Monitoring the rise and fall of the microbiome 2Monitoring the rise and fall of the microbiome 3Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
... ) today announced that Dan Maher , Senior Vice President of Product Development of BioMarin, will present a company update at the Barclays Capital Global Healthcare Conference in ... ... ... ...
... ... pressure switches and pressure transmitters moves to Hatfield, Pa. , ... Hatfield, PA (Vocus) March 17, 2010 -- ... a new production line for the recently acquired pressure gauge product family at its ...
... ... generation business intelligence software, today announced the availability of Centrifuge 1.8, the latest version ... ... Centrifuge Systems, Inc. , a leading provider of next generation business intelligence software, ...
Cached Biology Technology:BioMarin to Present at the Barclays Capital Global Healthcare Conference 2BioMarin to Present at the Barclays Capital Global Healthcare Conference 3Brooks Instrument Opens Pressure Gauge Production Line 2Brooks Instrument Opens Pressure Gauge Production Line 3Centrifuge Releases New Data Visualization Software 2Centrifuge Releases New Data Visualization Software 3
(Date:7/25/2014)... engineering at the University of Houston, has written ... organ development., "Introduction to Tissue Engineering: Applications and ... the field of artificial organ development. Metin Akay, ... UH, served as a series editor on the ... published books on the subject of growing artificial ...
(Date:7/25/2014)... of Adelaide has opened the way for the development of ... In Australia, annual barley production is second only to wheat ... of the most important diseases of barley. , Senior Research ... of special growths on the cell walls of barley plants ... , The research, by the ARC Centre of Excellence in ...
(Date:7/25/2014)... a complex congenital central nervous system disease that ... neural tubes during the embryonic phase. Many patients ... incontinence and neurocognitive retardation. Such problems decrease the ... Researchers at Ankara Physical Medicine and Rehabilitation Education ... in children with SB, using the Pediatric Evaluation ...
Breaking Biology News(10 mins):University of Houston researcher publishes textbook on tissue engineering 2New hope for powdery mildew resistant barley 2
... formation of the centromere, a key cellular structure in powering ... earned him a paper in Nature Cell Biology ... year, for a maximum of five years. Lars Jansen ... in Portugal, last year to head the Epigenetic Mechanisms group. ...
... repairing DNA strands damaged by oxidation leads to several ... contributes to the development of cancer. That,s the conclusion ... by researchers at the National Institute of Standards and ... the New York University School of Medicine (NYUSM). ...
... CHICAGO The American Dietetic Association has released an ... diets, if well-planned, are healthful and nutritious for adults, ... treat chronic diseases including heart disease, cancer, obesity and ... of the Journal of the American Dietetic Association ...
Cached Biology News:Double success for Instituto Gulbenkian de Ciencia scientists working on chromosome segregation 2Genetically engineered mice yield clues to 'knocking out' cancer 2ADA releases updated position paper on vegetarian diets 2